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Abstract
CD30 is a cytokine receptor belonging to the tumor necrosis factor superfamily (TNFRSF8) that 
acts as a regulator of apoptosis. The presence of CD30 antigen is important in the diagnosis of 
Hodgkin’s disease and anaplastic large cell lymphoma. There have been sporadic reports of CD30 
expression in non-lymphoid tumors, including malignant mesothelioma. Given the remarkable 
success of brentuximab vedotin, an antibody-drug conjugate directed against CD30 antigen, in 
lymphoid malignancies, we undertook a study to examine the incidence of CD30 in mesothelioma 
and to investigate the ability to target CD30 antigen in mesothelioma. Mesothelioma tumor 
specimens (N = 83) were examined for CD30 expression by immunohistochemistry. Positive 
CD30 expression was noted in 13 mesothelioma specimens, primarily those of epithelial 
histology. There was no significant correlation of CD30 positivity with either tumor grade, stage 
or survival. Examination of four mesothelioma cell lines (H28, H2052, H2452, and 211H) for 
CD30 expression by both FACS analysis and confocal microscopy showed that CD30 antigen 
localized to the cell membrane. Brentuximab vedotin treatment of cultured mesothelioma cells 
produced a dose-dependent decrease in cell growth and viability at clinically relevant 
concentrations. Our studies validate the presence of CD30 antigen in a subgroup of epithelial-type 
mesothelioma tumors and indicate that selected mesothelioma patients may derive benefit from 
brentuximab vedotin treatment.
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Malignant mesothelioma is a locally aggressive tumor with the most common form being 
malignant pleural mesothelioma, representing approximately 70% of all mesothelioma 
diagnoses. Diagnosis at an early stage of the disease is often difficult because of its 
nonspecific signs and symptoms, and consequently a large majority of the patients are 
initially diagnosed at an advanced stage. Mesothelioma is associated with occupational 
asbestos exposure in most industrialized countries (1). Many emerging countries have yet to 
prohibit asbestos usage, which predicts that a great number of the patients will suffer from 
this disease in the future. In addition, there is also growing concern that the widespread use 
of nano-sized particles for medical and industrial purposes may create new risks for 
developing mesothelioma. Treatment for advanced malignant mesolthelioma is comprised of 
combination chemotherapy containing platinum and pemetrexed (2). Since approval of this 
regimen for mesothelioma there have been no therapeutic advances for the treatment of this 
disease. Thus, there is an urgent need to develop new therapeutic strategies against this 
disease.
Antibody-based therapies and immunotoxins have shown remarkable therapeutic activities 
in various tumors and might represent a promising approach against mesothelioma (2, 3). 
This approach targets antigens specifically expressed on cancerous cells, resulting in an 
increased therapeutic efficacy with minimal systemic toxicity. CD30 is a member of the 
tumor necrosis factor receptor super family (TNFRSF8) and is highly expressed in 
lymphoma with limited expression in healthy tissues, making it an ideal target for antibody-
based therapies (4-8). Recently, in clinical trials for relapsed/refractory Hodgkin lymphoma 
(HL) and anaplastic large cell lymphoma (ALCL) (9, 10), brentuximab vedotin 
demonstrated high response rates as a single agent leading to its accelerated approval by the 
Food and Drug Administration (FDA) for treatment of these lymphomas under the brand 
name Adcetris®. Brentuximab vedotin is an antibody-drug conjugate, which couples an 
anti-CD30 antibody (SGN-30) to the synthetic anti-tubulin agent MMAE (11).
While several reports have identified CD30 antigen in other types of solid tumors, including 
malignant mesothelioma (4, 5, 12), these findings have not been systematically followed up, 
which is important for broadening the family of CD30-positive cancers that are potential 
targets for brentuximab vedotin. Here we validate the presence of CD30 in a panel of 
mesothelioma tumors by immunohistochemistry and demonstrate its cell surface location in 
mesothelioma cell lines by confocal microscopy and flow cytometry. Importantly, the 




The human small cell lung cancer cell line H526 and mesothelioma cell lines H2052, 
H2452, 211H and H28 were purchased from the American Type Culture Collection 
(Manassas, VA) within the last three years and used at a passage of ≤ 7. These thoracic cell 
lines were not authenticated because of their direct purchase from the ATCC and low 
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passage number. Karpas cells were a gift from Dr. H. Koon and while not authenticated, 
served as a positive control and responded to drug treatment in accordance with published 
reports (9, 10, 13, 14) Cell lines were maintained in Dulbecco's Modified Eagle Medium 
(DMEM)/Ham's F-12 medium supplemented with 10% (v/v) fetal bovine serum (FBS, 
Hyclone, ThermoFisher Scientific, Waltham, MA) in a 5% CO2 humidified incubator at 
37°C.
Confocal Microscopy
Mesothelioma cells were seeded onto a glass-bottomed culture dish (MatTek Corp.). Cells 
were fixed with 4% formaldehyde diluted in PBS. After 1 h blocking with 1% bovine serum 
albumin in PBS, cells were incubated with a rabbit polyclonal anti-CD30 antibody (Novus 
Biologicals, NBP1-72175; 1:100) at room temperature for 2 h and washed three to four 
times with PBS. Incubation with Alexa Fluor 488–conjugated goat anti-rabbit IgG 
(Molecular Probes; 1:500) was done for 1 h at room temperature, followed by repeated 
washes using PBS. After subsequent staining of nuclei with 1 μM DRAQ5 in PBS for 30 
min, confocal images were obtained on a Zeiss LSM510 NLO laser-scanning microscope 
using single-line (488 nm) or multitrack sequential excitation (488 and 633 nm). Images 
were acquired and processed with Zeiss LSM Image Browser software.
Flow cytometry analysis of CD30 expression
Expression of CD30 on the surface of mesothelioma cell lines was confirmed by FACS 
analysis, using a fluorescent dye conjugated secondary antibody Alexa Fluor 488–
conjugated anti-rabbit IgG (Molecular Probes; 1:500). Mesothelioma cells were collected by 
centrifugation, fixed with ethanol by incubating at least 30 min at room temperature. 
Centrifuged again and supernatant decanted off. Cells were permeablized or non-
permeabilized with or without Triton X-100 (0.1% in PBS) for 10 min, briefly centrifuged 
and the resulting supernatant removed. The cells were suspended in FACS buffer with or 
without diluted primary (rabbit polyclonal anti-CD30 antibody, NBP1-72175, 1:100) or 
secondary (Alexa Fluor 488–conjugated anti-rabbit IgG, 1:500) antibodies followed by 30 
min incubation on ice. The stained cells were analyzed on a LSR II flow cytometer (BD 
Biosciences; San Jose, CA). FACS data were analyzed by using FlowJo software (Tree Star, 
Ashland, OR).
Cell proliferation analysis
Cell growth and viability were assessed in manually counted cells by either trypan blue dye 
exclusion or the MTS assay, as described previously (15).
Cell cycle analysis
Karpas 299, H2052, H2452 and H526 cells were seeded in 100 mm dishes and the next day 
treated with 0.05 μg to 60 μg /mL of brentuximab vedotin for 48 h. All attached and floating 
cells were washed with PBS and fixed in 0.125% formaldehyde followed by methanol. After 
incubation at −20°C, cells were washed with PBS and incubated for 45 min at 4°C in 50 
μg/ml propidium iodide, 0.1% Nonidet P-40, 20 μg/ml RNase A and 0.1% sodium azide in 
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PBS. Propidium iodide fluorescence was measured on an EPICS XL-MCL cytometer 
(Beckman Coulter, Pasadena, CA).
Immunohistochemistry
The TMA slides were obtained from the National Mesothelioma Virtual Bank (NMVB) 
(http://mesotissue.org/). The slides were deparaffinized with xylene then transferred through 
graded ethanol to H2O. Endogenous peroxidase activity was blocked by a 10-min incubation 
in a 3% hydrogen peroxide solution. Antigen retrieval was performed by boiling the slides in 
a pressure cooker filled with a sodium citrate buffer (pH 6.0). After antigen retrieval, the 
slides were blocked using Background Sniper (Biocare, BS966M) for 20 min. The tissues 
were incubated with a mouse monoclonal anti-human CD30 antibody (Cell Marque/Clone 
Ber-H2) overnight at 4°C. Bound antibody was detected as described previously (16). The 
intensity of immunostaining for CD30 was scored visually by a thoracic pathologist and 
stratified into three staining groups based on staining intensity and percentage of tumor cells 
involved. Multiple cores for a single tumor sample were viewed to determine the score.
Statistical Analysis
All the described experiments were done more than three times, and the data are presented 
as mean values ± SEM. P values were determined by t test using either Prism or SAS 
software (SAS Institute, Cary, NC). P < 0.05 was considered statistically significant.
Results
CD30 mRNA expression is high in mesothelioma tissues
We analyzed the gene expression patterns of CD 30 in all types of adult solid tumor cancer 
cell lines in the Cancer Cell Line Encyclopedia (CCLE) database (http://
www.broadinstitute.org/ccle/home) (17). When we compared cell lines derived from solid 
tumors we found the highest CD30 expression levels in mesothelioma, excluding 
lymphomas (Figure 1A). Based on these observations, we searched the Oncomine database 
(https://www.oncomine.org/resource/login.html) for expression in tumor tissues. A study by 
Gordon et al (18) performed expression profiling in thoracic cancers. When we specifically 
looked at CD30 expression we found that mesothelioma showed significantly higher 
expression of CD30 (p<0.0001) compared to adenocarcinoma (Figure 1B). A study by 
Lopez-Rios et al (19) performed expression profiling in mesothelioma subtypes. When we 
specifically looked at CD30 expression in this dataset we observed significantly higher 
CD30 expression in epithelioid compared to biphasic (p<0.006) and sarcomatoid (p<0.001) 
subtypes of mesothelioma tumors. Biphasic expression was not statistically different from 
sarcomatoid (p <0.506) (Figure 1C).
CD30 protein is expressed in mesothelioma tumors
We obtained tissue microarrays from the National Mesothelioma Virtual Bank (NMVB) to 
determine the level of CD30 staining in mesothelioma tumors by immuno-histochemistry. 
Descriptive statistics for the entire cohort of analyzed samples, as well as for CD30+ 
samples, is given in Table 1. The cohort demonstrated a typical distribution of histologic 
subtypes. Overall, CD30+ expression was noted in 13 out of 83 total mesothelioma 
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specimens and 12 of the CD30+ tumors demonstrated epithelial histology. The incidence of 
CD30 positivity was 4.6% in the biphasic and sarcomatoid group vs. 19.7% for the 
epithelioid group, approaching significance (p < 0.094). Membrane-associated staining was 
evident in the highest scoring tumors, similar to that observed in the Hodgkin’s lymphoma 
positive control. Representative results of CD30 positivity are shown in Figure 2 at three 
different magnifications. Diffuse cytoplasmic staining of variable intensity was observed in 
lower scoring mesothelioma tumors. The percentage of tumor cells stained positive varied 
greatly, from nearly the whole tumor core down to only 5-10% of the core, as shown in the 
low power images in Figure 2, and generally decreased with scoring grade. One epithelioid 
core demonstrated 3+ and three demonstrated 2+ staining and the rest exhibited 1+ staining. 
The remaining CD30+ tumor was a high grade, biphasic metastatic tumor that demonstrated 
1+ staining. We also looked for CD30 expression in three mesothelioma specimens obtained 
from our own hospital and found only one positive sample, although it demonstrated strong 
(3+) CD30 expression (data not shown). The mesothelioma cohort contained survival data 
on 63 patients, however univariate analyses using both Kaplan-Meier (p<0.935) and 
continuous measurement Cox regression models (p<0.82) predicted no statistical 
significance of CD30 positivity on overall survival.
CD30 protein is expressed on the cell surface of mesothelioma cells
The immunohistochemistry of CD30 in tumors clearly demonstrated a pattern of membrane-
associated staining in some samples, which may represent an important feature in predicting 
sensitivity to brentuximab vedotin. We therefore sought to validate this finding in 
mesothelioma cell lines. We obtained all the available mesothelioma cell lines from the 
ATCC and determined the subcellular localization of CD30 by confocal microscopy. Data 
from the CCLE indicated that all four mesothelioma cells expressed CD30 mRNA. Figure 
3A shows that CD30 staining outlines the shape of two mesothelioma cell lines, H2052 and 
H2452, consistent with CD30 residing on the cell membrane. Further examination of other 
focal planes confirmed this finding and detected little or no staining of cytoplasm. Similar 
results were obtained for 211H and H28 cells (data not shown). These results indicated that 
in mesothelioma cell lines that CD30 resides on, or near, the cellular membrane.
In order to determine if CD30 is expressed on the cell surface, H2052 and H2452 cells were 
fixed with ethanol, prior to being stained with an anti-CD30 antibody, and then analyzed by 
flow cytometry (Figure 3B). Both cell lines were found to be positive for CD30 when intact 
(non-permeabilized). However, when cells were permeabilized with Triton X-100 prior to 
staining to reveal intracellular CD30, variable amounts of additional CD30 were detected. 
Taken together, these results indicate that a significant amount of cellular CD30 antigen is 
located on the cell-surface of mesothelioma cells.
Brentuximab vedotin decreases cell growth and viability in mesothelioma cells
We hypothesize that the expression of CD30 on the cell surface should sensitize 
mesothelioma cells to brentuximab vedotin. We therefore investigated the effect of this 
antibody-drug conjugate on cell growth in mesothelioma cell lines. We selected Karpas 299, 
a CD30+ lymphoma cell line, as a positive control and H526, a small cell lung cancer cell 
line, as a negative control for these experiments. Cell growth determination by viable cell 
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count demonstrated that Karpas cells were sensitive to brentuximab vedotin in a dose-
dependent manner after 48 h of treatment, as expected, whereas H526 cells were largely 
resistant, indicating that most of the toxic drug remained conjugated to the CD30 antibody 
(Figure 4A). The two mesothelioma cell lines tested, H2052 and H2452, were both sensitive 
to the antibody-drug conjugate, with H2052 cells demonstrating more sensitivity than 
H2452 cells, although both were less sensitive than Karpas cells. We further investigated the 
effect of brentuximab vedotin on mesothelioma cell viability using the MTS assay. 
Treatment of H2052 and H2452 cells for 48 h induced a dose-dependent decrease in cell 
viability compared to untreated control cells (Figure 4B). As expected, the Karpas cells 
demonstrated greater sensitivity than mesothelioma cells whereas the H526 cells were 
resistant.
To confirm that brentuximab vedotin induced cell death in mesothelioma cells, we 
performed cell cycle analysis by flow cytometry. As shown in Figure 5, brentuximab 
vedotin greatly increased the proportion of Karpas cells in the G0 (sub G1) phase at the 
lowest dose after 48 h of incubation. This effect was not observed with H526 cells at any 
dose. Importantly, the two mesothelioma cell lines tested, H2052 and H2452, also 
demonstrated a dose-dependent increase in the proportion of cells in the sub G1 phase in 
response to brentuximab vedotin treatment, with H2052 cells again being more sensitive to 
drug than H2452 cells. The increased proportion of mesothelioma cells in sub G1 phase was 
accompanied by a parallel increase in cells in the G2/M phase. This is consistent with the 
anti-microtubule activity of the conjugated drug in brentuximab vedotin. MMAE, to produce 
mitotic arrest and G2/M blockade. Taken together, these results demonstrate that 
brentuximab vedotin treatment has an inhibitory effect on cell growth and survival in 
mesothelioma cells.
Discussion
The goal of this study was to determine the therapeutic potential of targeting CD30 with 
brentuximab vedotin in mesothelioma. We looked for CD30 expression in the largest cohort 
of mesothelioma tumors studied to date and found that only 15.6% (13 of 83 tumors) were 
positive for CD30 expression using an antisera routinely used in the diagnosis of Hodgkin’s 
lymphoma. There was a trend toward CD30 expression in mesothelioma tumors with 
epithelioid histology and high grade. Previous studies of CD30 expression in mesothelioma 
had noted expression in a single index case (4), two of five tumors (20) and two of eight 
tumors and 16 of 28 pleural and peritoneal effusions (5)
Although CD30 expression was not prognostic for overall survival in our study, of greater 
importance was whether or not CD30 expression could predict sensitivity to the antibody-
drug conjugate targeting CD30, brentuximab vedotin. We used mesothelioma cell lines as a 
model system to test this hypothesis. Our results demonstrated that CD30 was expressed on 
the cell surface of mesothelioma cells using two complementary methods, confocal 
microscopy and FACS analysis. We then demonstrated that brentuximab vedotin decreased 
cell growth and viability in CD30 positive mesothelioma cells by three different methods. It 
is important to highlight three crucial points in these experiments. First, the doses of 
brentuximab vedotin used in our study, 0.5, 15 and 60 μg/ml, were within the range of drug 
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clinically achievable. That is, the typical Cmax and AUC for brentuximab vedotin after a 
single 1.8 mg/kg dose was approximately 32 μg/ml and 80 μg /ml/day, respectively, in a 
phase I study (Acedris® insert). Second, the loss of mesothelioma cell viability after 
brentuximab vedotin treatment was associated with an increase in the proportion of cells in 
G2/M phase, as expected since the antibody conjugated toxin, MMAE, is a microtubule 
inhibitor. Third, there was no effect of brentuximab vedotin on a small cell lung cancer cell 
line, H526, suggesting therapeutic specificity.
It is unclear, however, to what extent our demonstration of brentuximab vedotin sensitivity 
in vitro using cultured mesothelioma cells is translatable to clinical drug sensitivity in 
mesothelioma patients. In this regard a recent interim report from a phase II study by Jalal et 
al on brentuximab vedotin in patients with malignant mesothelioma reported that 34% were 
positive for CD30 expression and that five positive responses were obtained to drug 
treatment out of 21 evaluable CD30+ patients (21). Although we obtained a lower 
percentage of CD30+ tumors (15.6%), likely attributable to scoring methods, the interim 
results of this phase II study confirm our hypothesis that a subgroup of malignant 
mesothelioma patients will respond to brentuximab.
It is clear from our study that mesothelioma tumor specimens demonstrated a range of CD30 
expression, both in terms of their staining intensity and percentage of tumor cells involved. 
However, there was clearly a subset of high-scoring tumors that demonstrated obvious 
membrane-associated staining. It is intriguing to think that these tumors may demonstrate 
the greatest sensitivity to brentuximab vedotin. It has been suggested, however, that the 
MMAE toxin is freely diffusible into the surrounding microenvironment once it is 
internalized and cleaved from CD30 antibody in target CD30+ lymphoma cells, as 
evidenced by the sometimes-low occupancy (3%) of CD30-binding sites in lymphoma cells 
from highly responsive patients treated with brentuximab vedotin (22). Thus, the efficacy of 
brentuximab vedotin in mesothelioma tumors may not simply correlate with CD30 
positivity. The answer to these questions awaits more detailed analysis of CD30 expression 
in clinical trials of brentuximab vedotin in malignant mesothelioma.
Acknowledgement
We are thankful to the Mesothelioma Research Bank [CDC NIOSH 1-U19-OH009077-01 National Mesothelioma 
Virtual Bank for Translational Research] for providing us with the tissue microarrays of mesothelioma. We are 
thankful to Dr. H. Koon at the Case Comprehensive Cancer Center for providing the Karpas cell line. We are also 
very thankful to Karen McCall for her support in the project.
Financial Support:
Supported by funds from the University Hospitals Seidman Cancer Center (A. Dowlati) as well as the Tissue 
Resources Core Facility and the Biostatistics & Bioinformatics Core Facility of the Case Comprehensive Cancer 
Center (National Cancer Institute P30 CA043703).
References
1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005; 353:1591–
603. [PubMed: 16221782] 
Dabir et al. Page 7













2. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, et al. Phase I clinical trial of the 
chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing 
cancers. Clin Cancer Res. 16:6132–8. [PubMed: 21037025] 
3. Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, et al. A recombinant immunotoxin 
against the tumor-associated antigen mesothelin reengineered for high activity, low off-target 
toxicity, and reduced antigenicity. Mol Cancer Ther. 12:48–57. [PubMed: 23136186] 
4. Dunphy CH, Gardner LJ, Bee CS. Malignant mesothelioma with CD30-positivity. A case report and 
review of the literature. Arch Pathol Lab Med. 2000; 124:1077–9. [PubMed: 10888787] 
5. Durkop H, Foss HD, Eitelbach F, Anagnostopoulos I, Latza U, Pileri S, et al. Expression of the 
CD30 antigen in non-lymphoid tissues and cells. J Pathol. 2000; 190:613–8. [PubMed: 10727988] 
6. Kadin ME. Regulation of CD30 antigen expression and its potential significance for human disease. 
Am J Pathol. 2000; 156:1479–84. [PubMed: 10793058] 
7. Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin 
lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol. 3:209–25. [PubMed: 
23606932] 
8. Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, et al. CD30 
expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and 
distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP 
Consortium Program Study. Blood. 121:2715–24. [PubMed: 23343832] 
9. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading 
on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004; 
10:7063–70. [PubMed: 15501986] 
10. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development 
of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003; 
21:778–84. [PubMed: 12778055] 
11. Deng C, Pan B, O'Connor OA. Brentuximab vedotin. Clin Cancer Res. 19:22–7. [PubMed: 
23155186] 
12. Garcia-Prats MD, Ballestin C, Sotelo T, Lopez-Encuentra A, Mayordomo JI. A comparative 
evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural 
tumours. Histopathology. 1998; 32:462–72. [PubMed: 9639123] 
13. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-
vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor 
activity. Blood. 2003; 102:1458–65. [PubMed: 12714494] 
14. Kim KM, McDonagh CF, Westendorf L, Brown LL, Sussman D, Feist T, et al. Anti-CD30 
diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther. 2008; 7:2486–97. 
[PubMed: 18723494] 
15. Dabir S, Kluge A, Dowlati A. The association and nuclear translocation of the PIAS3-STAT3 
complex is ligand and time dependent. Molecular cancer research : MCR. 2009; 7:1854–60. 
[PubMed: 19903771] 
16. Dabir S, Kluge A, Kresak A, Yang M, Fu P, Groner B, et al. Low PIAS3 Expression in Malignant 
Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival. Clin 
Cancer Res. 2014; 20:5124–32. [PubMed: 25124686] 
17. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell 
Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 
483:603–7. [PubMed: 22460905] 
18. Gordon GJ, Jensen RV, Hsiao LL, Gullans SR, Blumenstock JE, Ramaswamy S, et al. Translation 
of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in 
lung cancer and mesothelioma. Cancer research. 2002; 62:4963–7. [PubMed: 12208747] 
19. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, et al. Global gene expression 
profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion 
as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer 
research. 2006; 66:2970–9. [PubMed: 16540645] 
20. Sharman JP, Goldschmidt JH, Burke JM, Hellerstedt BA, McIntyre K, Yasenchak CA, et al. CD30 
expression in nonlymphomatous malignancies. J Clin Oncol. 2012; 30(suppl) abstr 3069. 
Dabir et al. Page 8













21. Jalal SI, Einhorn L, Shapiro GI, Hilton J, Wheler J, Dowlati A, Josephson N, Sharman J, Burke 
JM. Brentuximab Vedotin in Patients with CD30+ Mesothelioma. Mesothelioma, Thymic 
Malignancies, and Other Thoracic Malignancies. Int J Rad Oncol. 2014; 90(5):S8.
22. Fromm JR, McEarchern JA, Kennedy D, Thomas A, Shustov AR, Gopal AK. Clinical binding 
properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an 
antibody-drug conjugate for CD30-positive lymphoid neoplasms. Clin Lymphoma Myeloma Leuk. 
12:280–3. [PubMed: 22542449] 
Dabir et al. Page 9













Figure 1. Mesothelioma shows high CD30 expression in public datasets
(A) Gene expression pattern for CD30 across solid tumor cancer cell lines in the Cancer Cell 
Line Encyclopedia (CCLE) data base (B) Whisker plots showing the Log2 median centered 
intensity of CD30 expression in Gordon lung dataset (18). Compared to adenocarcinoma, 
CD30 expression in mesothelioma tissue samples is significantly higher. (C) Whisker plots 
of the Log2 median centered intensity of CD30 expression in Lopez-Rios dataset (19) shows 
higher CD30 expression in epithelioid compared to biphasic and sarcomatoid.
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Figure 2. Mesothelioma tumor specimens demonstrate high CD30 expression
CD30 expression was examined by immuno-histochemistry (IHC) with an anti-BerH2 
antibody used for the clinical diagnosis of Hodgkin disease. The positive control is Hodgkin 
lymphoma. Rectangles show area magnified in image below. The 3+ core was scored higher 
than the 2+ core due to a greater area of positivity, not because of intensity.
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Figure 3. Analysis of CD30 expression in mesothelioma cell lines
(A) Confocal analysis of mesothelioma cell lines. The DAPI stain identifies the nucleus. (B) 
Mesothelioma CD30 expression by FACS analysis. In these experiments, control is staining 
in the absence of primary antibody.
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Figure 4. Effect of brentuximab vedotin treatment on cell growth and viability
(A) Mesothelioma cell lines H2052, H2452, 211H and positive control Karpas 299 treated 
with brentuximab vedotin and cells were counted on day 1 and 2. (B) MTS assay of cell 
proliferation.
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Figure 5. Effect of brentuximab vedotin treatment on cell cycle
Results demonstrate a dose response of mesothelioma cells to brentuximab vedotin 
treatment after 48 h. The percentage of cells in the G0, G1, S and M phase is shown in the 
figure.
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High 24 7 0.163
Intermediate and low 35
a
incomplete staging and grading data available
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